Edition:
United States

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

9.05USD
19 Jan 2017
Change (% chg)

$-0.17 (-1.84%)
Prev Close
$9.22
Open
$9.20
Day's High
$9.23
Day's Low
$9.04
Volume
33,734
Avg. Vol
152,575
52-wk High
$16.80
52-wk Low
$7.20

Select another date:

Wed, Nov 9 2016

BRIEF-Omeros Q3 loss per share $0.34

* Omeros Corporation reports third quarter 2016 financial results

BRIEF-Omeros files orphan drug application for OMS721 in Immunoglobulin A nephropathy

* Files orphan drug application for OMS721 in Immunoglobulin A nephropathy

BRIEF-Omeros announces positive data from mid-stage clinical trial evaluating PPAR-Gamma agonist in heroin users

* Trial demonstrated that compound statistically significantly reduced drug craving and measures of anxiety in heroin users maintained on sublingual buprenorphine/naloxone

BRIEF-Omeros announces $125 million new credit facility

* New credit facility consists of an $80 million term loan to be drawn by company within ten business days

BRIEF-Omeros Corp announces positive data from OMS721 phase 2 trial

* Omeros announces positive data from OMS721 phase 2 trial in patients with stem cell transplant-associated thrombotic microangiopathy

BRIEF-Omeros announces positive data from OMS721 phase 2 clinical trial in renal diseases

* Omeros announces positive data from OMS721 Phase 2 clinical trial in renal diseases

BRIEF-Omeros announces pricing of public offering of common stock

* Omeros announces pricing of public offering of common stock

BRIEF-Omeros announces public offering of common stock

* Intends to use net proceeds for funding research and development expenses for its clinical OMS721 program and clinical trials

BRIEF-Omeros confirms late-stage development plan for OMS721 with EMA

* Omeros corporation confirms oms721 phase 3 development plan with european medicines agency

Select another date: